Pfizer Recalls Smoking Cessation Drug Chantix, Citing Presence of Possible Carcinogen




WASHINGTON, D.C. — Pfizer is recalling all lots of Chantix 0.5 mg and 1 mg. tablets due to the presence of a possible carcinogen, N-nitroso-varenicline, at or above acceptable limits, the Food and Drug Administration has announced.

In a Sept. 17 MedWatch alert, the agency explained that Pfizer has not received reports of adverse events related to the recall and that “the health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline.”

“Long-term ingestion of N-nitroso-varenicline may be associated with a theoretical potential increased cancer risk in humans, but there is no immediate …






UPCOMING CONFERENCES




HarrisMartin's Masters of Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024

MORE DETAILS